Afficher la notice abrégée

Factors associated with COVID-19 severity in patients with spondyloarthritis: Results of the French RMD COVID-19 cohort

dc.rights.licenseopenen_US
dc.contributor.authorPERROT, L.
dc.contributor.authorBOYER, L.
dc.contributor.authorFLIPO, R.-M.
dc.contributor.authorMAROTTE, H.
dc.contributor.authorPERTUISET, E.
dc.contributor.authorMICELI, C.
dc.contributor.authorTHOMAS, T.
dc.contributor.authorSEROR, R.
dc.contributor.authorCHAZERAIN, P.
dc.contributor.authorROUX, N.
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorRICHEZ, Christophe
dc.contributor.authorPHAM, T.
dc.contributor.authorCONSORTIUM, FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE
dc.date.accessioned2024-05-03T09:40:51Z
dc.date.available2024-05-03T09:40:51Z
dc.date.issued2023
dc.identifier.issn1297-319Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/199604
dc.description.abstractEnObjectives: The objective of the current study was to evaluate the severity of COVID-19 and identify factors associated with severe disease outcomes in patients with spondyloarthritis (SpA), a chronic inflammatory rheumatic and musculoskeletal disease (RMD). Methods: We utilized patient data from the French national multicenter RMD COVID-19 cohort (NCT04353609). The primary outcome was to describe COVID-19 characteristics in patients with SpA based on disease severity of COVID-19 (mild, moderate or severe) with serious infection including moderate and severe cases. The secondary outcome was to identify the factors associated with serious COVID-19 classification. Results: Among the 626 patients with SpA (56% female, mean age 49 ± 14 years) from the French RMD cohort, COVID-19 severity was mild in 508 (81%), moderate in 93 (15%), and severe in 25 (4%) patients. Clinical signs and symptoms of COVID-19 were reported in 587 (94%) patients, with the most frequent presented symptom of fever (63%) and cough (62%), followed by flu-like symptoms (53%), agueusia (39%), anosmia (37%), dyspnea (32%) and diarrhea (19.9%). COVID-19 severity was associated with corticosteroid therapy (OR = 3.08 [95% CI: 1.44–6.58], P = 0.004) and age (OR = 1.06 [95% CI: 1.04–1.08], P < 0.001) while use of tumor necrosis factor inhibitor (TNFi, OR = 0.27 [95% CI: 0.09–0.78], P = 0.01) was associated with less severe disease. We did not identify an association between NSAID use and COVID-19 severity. Conclusions: In this study, the majority of patients with SpA had a favorable COVID-19 outcome. We confirmed age and corticosteroids therapy had a negative impact on disease outcomes while TNFi use was protective. © 2023 Société française de rhumatologie
dc.language.isoENen_US
dc.subject.enCOVID-19
dc.subject.enRheumatic musculoskeletal diseases
dc.subject.enSpondyloarthritis
dc.subject.enPsoriatic arthritis
dc.title.enFactors associated with COVID-19 severity in patients with spondyloarthritis: Results of the French RMD COVID-19 cohort
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.jbspin.2023.105608en_US
dc.subject.halSciences du Vivant [q-bio]/Immunologieen_US
dc.identifier.pubmed37414137en_US
bordeaux.journalJoint Bone Spineen_US
bordeaux.volume90en_US
bordeaux.hal.laboratoriesImmunoConcEpT - UMR 5164en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.description.error<?xml version="1.0" encoding="utf-8"?> <sword:error xmlns:sword="http://purl.org/net/sword/error/" xmlns="http://www.w3.org/2005/Atom"> <title>ERROR</title> <updated>2024-05-04T01:03:58+02:00</updated> <author> <name>HAL SWORD API Server</name> </author> <source> <generator uri="https://api.archives-ouvertes.fr/sword" version="1.0">hal@ccsd.cnrs.fr</generator> </source> <sword:treatment>processing failed</sword:treatment> <sword:verboseDescription>Internal server error: Firstname (Fai2r/sfr/snfmi/sofremip/cri/imidiate) is invalid</sword:verboseDescription> <link rel="alternate" href="https://api.archives-ouvertes.fr" type="text/html"/> </sword:error>
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Joint%20Bone%20Spine&amp;rft.date=2023&amp;rft.volume=90&amp;rft.issue=6&amp;rft.eissn=1297-319X&amp;rft.issn=1297-319X&amp;rft.au=PERROT,%20L.&amp;BOYER,%20L.&amp;FLIPO,%20R.-M.&amp;MAROTTE,%20H.&amp;PERTUISET,%20E.&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
ImmunoConcept_JointBoneSpine_2 ...
Taille:
277.0Ko
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée